A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: The application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 32-38

  Miah, A B ^a   Schick, U ^a   Bhide, S A ^a,b   Guerrero Urbano, M T ^a,b   Clark, C H ^a,b   Bidmead, A M ^a,b   Bodla, S ^a   Del Rosario, L ^a   Thway, K ^a   Wilson, P ^c   Newbold, K L ^a   Harrington, K J ^a,b   Nutting, C M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

head and neck squamous cell cancer; IMRT; parotid sparing; xerostomia

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER INCIDENCE; CANCER PAIN; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; DERMATITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OTOTOXICITY; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PAROTID GLAND; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; XEROSTOMIA; ADOLESCENT; CARCINOMA, SQUAMOUS CELL; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ECHOGRAPHY; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PRESCHOOL CHILD; RADIATION INJURIES; RADIATION RESPONSE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; PAROTID GLAND; PROSPECTIVE STUDIES; RADIATION INJURIES; TREATMENT OUTCOME; XEROSTOMIA; YOUNG ADULT;

EID: 84920700864     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.553     Document Type: Article

References (18)

1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl JMed 363: 24-35.
2. Bentzen SM, Saunders MI, Dische S, Bond SJ (2001) Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 60: 123-135.
3. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM (2008) Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-andneck cancer. Br J Cancer 99: 57-62.
4. DCTD, NCI, NIH, DHHS (2003) Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
5. Gillison ML (2004) Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31: 744-754.
6. Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ. Spanish Head and Neck Cancer Cooperative Group (TTCC) (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25: 216-225.
7. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882.
8. Mehanna H, Paleri V, West CM, Nutting C (2010) Head and neck cancer-Part 1: epidemiology, presentation, and prevention. BMJ 341: c4684.
9. Miah AB, Gulliford SL, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM (2013a) The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. Radiother Oncol 106: 346-351.
10. Miah AB, Gulliford SL, Clark CH, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM (2013b) Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol 106: 341-345.
11. National Cancer Intelligence Network (2008) Incidence and mortality from head and neck cancers in England 2002-2006.
12. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E. PARSPORT trial management group (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12: 127-136.
13. Patel SG, Shah JP (2005) TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 55: 242-258quiz 261-2, 264.
14. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris Jr CM, Haddad RI. TAX 324 Study Group (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715.
15. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66: 981-991.
16. Rubin P, Constine 3rd LS, Fajardo LF, Phillips TL, Wasserman TH (1995) EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 35: 9-10.
17. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. EORTC 24971/TAX 323 Study Group (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704.
18. Wilkins AC, Rosenfelder N, Schick U, Gupta S, Thway K, Nutting CM, Harrington KJ, Newbold K, Bhide SA (2013) Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: a matched-pair analysis. Oral Oncol 49: 615-619.